Nektar Therapeutics
NKTR
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.19B
Close$
$-30.55
140.2% downside
Current Fair Value
140.2% downsideOvervalued by 140.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.19 Billion |
|---|---|
| Enterprise Value | $2.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.73 |
| Beta | 1.14 |
| Outstanding Shares | 24,736,066 |
Return
| Return on Equity | -27.44% |
|---|---|
| Return on Assets | -20.71% |
| Return on Invested Capital | -19.11% |
Valuation & Multiples
| P/E Ratio | -9.08 |
|---|---|
| PEG | 77.31 |
| Price to Sales | 38.02 |
| Price to Book Ratio | 3.31 |
| Enterprise Value to Revenue | 38.24 |
| Enterprise Value to EBIT | -15.78 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.94
Average shareholder expectationRevenue Estimate
$10.43 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-1.97
Average shareholder expectationRevenue Estimate
$10.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 48.87% |
|---|---|
| Total Calls | 29,000▼ 96.95% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.63%▼ 106.91% |
|---|---|
| Total Invested | $425.58M▼ 77.83% |
| Investors Holding | 66▼ 154.00% |
ESG Score
No data
About Nektar Therapeutics
CEO: Howard Robin